Castleman's disease in two patients with spondyloarthritis treated by Tumor Necrosis Factor-alpha antagonists |
| |
| Institution: | 1. Department of Rheumatology, CIC/CRB 1404, Rouen University Hospital, Normandie Univ, UNIROUEN, 76000 Rouen, France;2. Department of Anatomy and Pathological Cytology, Henri Becquerel Center, 1 rue d’Amiens, 76000 Rouen, France;3. Department of Orthopaedics and Traumatology, Rouen University Hospital, 1, rue de Germont, 76000 Rouen, France;4. Department of Hematology, Henri Becquerel Center, 1, rue d’Amiens, 76000 Rouen, France;1. Service de rhumatologie, CHU de Strasbourg, Strasbourg, France;2. Centre national de références des maladies systémiques et auto-immunes rares Est Sud-Ouest (RESO), université de Strasbourg, Strasbourg, France;1. Epidemiology and Biostatistics Unit, Sorbonne Paris Cité Research Center Inserm U1153, Paris, France;2. Department of Rheumatology, Cochin Hospital, Paris, France;3. Paris Descartes University, Paris, France;4. François-Rabelais University, CNRS 7292, Tours, France;5. Biostatistics and Clinical Epidemiology research, Inserm U1153, Paris Diderot University, Paris, France;1. Rheumatology Unit Hospital, S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy;2. Immunology and Allergology Laboratory Hospital S. Giovanni di Dio, Azienda USL-Toscana Centro, Florence, Italy;3. Clinic of Rheumatology, Department of Medicine (DAME), ASUFC, Udine, Italy;1. Department of gastroenterology, Lyon Sud hospital, hospices civils de Lyon, Pierre-Bénite, France;2. University Claude-Bernard Lyon 1, 69007 Lyon, France;3. Inserm U1111, centre international de recherche en infectiologie (CIRI), Lyon, France;4. Department of rheumatology, Lyon Sud hospital, hospices civils de Lyon, Pierre-Bénite, France;5. Department of immunology, Lyon Sud hospital, hospices civils de Lyon, Pierre-Bénite, France;6. Inserm UMR1033, Lyon, France;7. Department of pediatry, Femme-mère-enfants hospital, hospices civils de Lyon, Bron, France;1. Division of Rheumatology, Geneva University Hospitals, 1206 Geneva, Switzerland;2. Centre for Epidemiology versus Arthritis, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, M13 9PT Manchester, United Kingdom |
| |
| Abstract: | Castleman's disease is a rare lymphoproliferative syndrome involving several anatomical and clinical entities. We report two cases of Castleman's disease in patients with spondyloarthritis (with and without psoriasis) treated with Tumor Necrosis Factor-alpha blockers. During follow-up, imaging examinations, carried out for disease assessment, fortuitously revealed a pelvic mass close to the psoas or an atypical cervical adenopathy. Both lesions were in moderate hypermetabolism on Positron emission tomography–computed tomography. After surgical excision and histological analysis, Castleman's disease was diagnosed without signs of malignancy. To the best of our knowledge, these are the first cases of Castleman's disease diagnosed in a context of spondyloarthritis treated with Tumor Necrosis Factor-alpha blockers. The relationship between these two pathologies and the link with Tumor Necrosis Factor-alpha blockers agents has not been explored in the literature until now. |
| |
| Keywords: | Castleman's disease Spondyloarthritis TNFalpha-blocker |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
